The prognostic value of the HALP score among patients diagnosed with Hodgkin lymphoma.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
The hemoglobin, albumin, lymphocyte, and platelet (HALP) score is an immune-nutritional biomarker utilized for prognostic assessment in oncology patients. It is determined by the formula: hemoglobin (g/L) × albumin (g/L) × lymphocytes (×109/L)]/platelets (×109/L). The objective of this study is to evaluate the prognostic value of the HALP score and its association with treatment response and survival outcomes among patients diagnosed with Hodgkin lymphoma (HL). Patients diagnosed with HL at the Hematology Clinic of Istanbul Başakşehir Çam and Sakura City Hospital between January 1, 2020, and January 1, 2025, were included in this study. A total of 100 patients with HL were included in the study. Patients were categorized based on the median HALP score of 23.72. Patients with a low HALP score exhibited significantly higher rates of stage IV disease, presence of B symptoms, and bulky masses. Patients with a high HALP score demonstrated significantly more complete response and less progression at the end of treatment. The analysis revealed a statistically significant 2.82-fold (95% confidence intervals: 1.14-6.97) increased risk of progression in patients with a HALP score of <23.72 compared to those with a score of ≥23.72. Patients with lower HALP scores exhibited more adverse disease characteristics. Lower HALP scores were associated with adverse disease characteristics, poorer treatment response, and shorter progression-free survival; however, HALP did not remain an independent prognostic factor in multivariate analysis.